Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot study

Cicero, Arrigo F G; Brancaleoni, Marco; Laghi, Luca; Donati, Franco; Mino, Marco

doi:10.1016/j.ctim.2005.07.008

Cited by 39 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improvement in LDL-cholesterolemia is quantitatively similar to that observed in other studies carried out with combined nutraceuticals with lipid-lowering activity, either containing statin-like substances [20] or different components [21]. The main advantage of the proposed approach is the lack of components as monakolin that sometimes (even if rarely) can have potentially dangerous pharmacological interactions [22].…”

Section: Discussionsupporting

confidence: 83%

Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial

Cicero

Bove

Gerocarni

et al. 2011

Mediterr J Nutr Metab

View full text Add to dashboard Cite

This is a double-blind, placebo-controlled clinical trial on a combined nutraceutical non containing statinlike substances in 40 patients affected by primary polygenic hypercholesterolemia. After 4 weeks of ATP III life-style improvement, patients were randomized to assume a combined nutraceutical or placebo 1 pill/day for 8 weeks. The tested nutraceutical contained octacosanols, tocotrienols and polymethoxylated flavones (offered by Ca.Di.Group Srl, Rome, Italy). When comparing the combined nutraceutical effect with the one of placebo, we observed that the combined nutraceutical assumption was associated with a significantly higher decrease in total cholesterol (p \ 0.001), LDL-cholesterol (p \ 0.001), triglycerides (p \ 0.001) and non HDL-cholesterol (p \ 0.001) than the control group. In the short term, the tested combined nutraceutical is well-tolerated and efficacious in reducing plasma lipid levels in subjects affected by primary polygenic hypercholesterolemia.

show abstract

Section: Discussionsupporting

confidence: 83%

Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial

Cicero

Bove

Gerocarni

et al. 2011

Mediterr J Nutr Metab

View full text Add to dashboard Cite

show abstract

“…The components of the combination were already known for their efficacy and tolerability in the general population. Policosanols and an extract of Monascus purpureus have been shown to inhibit respectively the synthesis and the activity of the hydroxyl-methyl-glutaryl coenzyme A reductase in a study by our group in more than 100 patients at low added cardiovascular risk in the setting of general medicine [18]. Further, the association of these nutraceuticals with berberine, an alkaloid available in numerous medicinal plants that reduce cholesterolaemia by increasing LDL-C receptor on the liver cell surface [19], has also been tested by our group in subjects with low added cardiovascular disease risk [20].…”

Section: Discussionmentioning

confidence: 98%

A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study

Cicero

Derosa

Bove

et al. 2008

Mediterr J Nutr Metab

Self Cite

View full text Add to dashboard Cite

This study was aimed at evaluating the tolerability of a nutraceutical combination with anticholesterolaemic action in patients intolerant of statin treatment. A total of 32 hypercholesterolaemic patients, all intolerant to at least two statin treatments, were enrolled in the ambulatory service. None of the enrolled patients was diabetic or undergoing secondary prevention of cardiovascular disease. Patients consumed one yoghurt with 2 g of added phytosterols each morning (Pro-Activ, Unilever, Milan, Italy) and one tablet of a registered combined nutraceutical (Armolipid Plus, Rottapharm, Monza, Italy). We tested the efficacy of the treatment after 4 and 6 months. One tablet of Armolipid Plus contains: berberine 500 mg, monacolin 3 mg, and policosanol 10 mg. After 3 months of treatment the patients showed a significant decrease in total cholesterol, low-density lipoprotein cholesterol and triglycerides, and a significant increase in the plasma level of high-density lipoprotein cholesterol. These results were maintained after 6 months of treatment without a significant change in the mean values.

show abstract

“…The product RMR is usually used to produce high concentration of natural red pigment. In current, RMR is also developed as the hypolipidemic functional food because of the production of monacolin K in many previous studies, RMR was found to lower blood cholesterol and triglyceride in animal tests and clinical studies (Cicero et al 2005;Lee et al 2006a;Lin et al 2005;Setnikar et al 2005;Wang et al 2000;Wei et al 2003). However, rice is used as the most common substrate of Monascus, but it is not sure the best substrate for the production of monacolin K and other functional ingredients.…”

Section: Ricementioning

confidence: 88%

Development of Monascus fermentation technology for high hypolipidemic effect

Lee¹,

Pan

2012

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Monascus species has been used as the traditional food fungus in Eastern Asia for several centuries. Monascus-fermented products are gradually developed as the popular functional food for the prevention of cardiovascular disease, but we know that culture condition affects the hypolipidemic effect of Monascus-fermented product. In the past, the cholesterol-lowering agent--monacolin K--is regarded as the most important hypolipidemic agent. Two natural yellow pigments--monascin and ankaflavin--are also proven as novel hypolipidemic agents in recent years. However, the hypolipidemic effect of Monascus-fermented product should contribute from monacolin K, monascin, ankaflavin, and other unknown functional ingredients. In addition to hypolipidemic effect, the safety concern of Monascus-fermented product is involved in the levels of mycotoxin--citrinin. The hypolipidemic effect and the production of these functional metabolites or mycotoxin are influenced by many factors such as the choice of culture substrates, carbon and nitrogen source, pH value, extra nutrients, and so on. Therefore, this review focused on the effect of various culture conditions and nutrients on the functional metabolites production, hypolipidemic effect as well as citrinin concentration, and further organized the fermentation technologies used by previous studies for the promotion of hypolipidemic effect and safety.

show abstract

Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot study

Cited by 39 publications

References 21 publications

Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial

Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial

A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study

Development of Monascus fermentation technology for high hypolipidemic effect

Contact Info

Product

Resources

About